| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2964 |
| Trial ID | NCT05281809 |
| Disease | B-Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphoblastic Leukemia | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia |
| Year | 2022 |
| Country | United States |
| Company sponsor | John Lister |
| Other ID(s) | 2021-114-WPH |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||